Alex's Lemonade Stand Foundation for Childhood Cancer

This project seeks to develop a targeted nanoparticle therapy that harnesses proinflammatory innate immune cells to reprogram TME immunity in high-risk NB. Currently, survival for high-risk metastatic NB remains ~50% at 5 years, even with chemotherapy given at maximal tolerated dosing, which itself imparts debilitating long-term sequelae in >90% of survivors.